There are currently 25 active clinical trials seeking participants for Healthy Participants research studies. The states with the highest number of trials for Healthy Participants participants are California, Florida, Texas and Kansas.
Study to Assess Drowsiness, Cognition, Fall Risk After Metaxalone 640 mg and Metaxalone 800 mg
NCT06348303
Recruiting
Every participant will receive Metaxalone in two (2) stages, one week after the other. A single dose of each Metaxalone dose will be taken one (1) time after a high fat meal which must be eaten within 30 minutes. Every participant will be given written tests to measure drowsiness, reaction time and thinking process and will also be asked to take walking tests to assess fall risk. Participation in this study will last approximately 2-4 weeks.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/05/2024
Locations: ClinOhio Research Institute, Columbus, Ohio
Conditions: Healthy Participants
Register for Updates
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
NCT06564389
Recruiting
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/15/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California
Conditions: Healthy Participants, Atopic Dermatitis
Register for Updates
A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
NCT06502379
Recruiting
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of AZD8965 via single and multiple ascending doses in healthy participants (including Japanese and Chinese participants), and to assess the effect of food on the safety, tolerability, and PK of orally administered AZD8965.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/14/2025
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
Register for Updates
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B)
NCT06349473
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) of SR604 in healthy participants (Part A) and to evaluate the safety, tolerability, PK, PD, and efficacy of SR604 in participants with Hemophilia A or Hemophilia B, with or without inhibitors (Part B).
Gender:
MALE
Ages:
Between 18 years and 60 years
Trial Updated:
04/11/2025
Locations: California Clinical Trials Medical Group (CCTMG), Glendale, California +6 locations
Conditions: Healthy Participants, Hemophilia A, Hemophilia B
Register for Updates
A Single and Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2389 in Healthy Participants
NCT06138795
Recruiting
This study will assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD2389 following single and multiple dose administration (SAD/MAD) to healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/10/2025
Locations: Research Site, Glendale, California
Conditions: Healthy Participants
Register for Updates
Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)
NCT06919991
Recruiting
The purpose of the study is to assess the effects of multiple doses of itraconazole (a strong CYP3A4 inhibitor) on single dose PK of casdatifan in healthy adults and to assess the effects of multiple doses of phenytoin (a strong CYP3A4 inducer) on single dose PK of casdatifan in healthy adults.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/10/2025
Locations: Celerion, Tempe, Arizona
Conditions: Healthy Participants
Register for Updates
A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants
NCT06713590
Recruiting
This study will be conducted to evaluate a Single-Dose Subcutaneous (SC) Axatilimab Compared With Intravenous Axatilimab in Healthy Participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/02/2025
Locations: Celerion, Inc, Tempe, Arizona
Conditions: Healthy Participants
Register for Updates
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
NCT06491550
Recruiting
This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B. Part C of this study will investigate the possibility of drug-drug interaction (DDI) between IV AZD4144 and oral rosuvastatin and furosemide by evaluating the PK of rosuvastatin and furosemide when administered alone and in combination with single IV dose of AZD4144
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/02/2025
Locations: Research Site, Glendale, California +1 locations
Conditions: Healthy Participants
Register for Updates
Drug-Drug Interaction Potential of Mavorixafor
NCT06914869
Recruiting
The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
04/02/2025
Locations: Parexel International LLC, Baltimore, Maryland
Conditions: Healthy Participants
Register for Updates
A Study to Assess New Formulations of TEV-56286
NCT06911567
Recruiting
The primary objective of the study is to assess the relative bioavailability of TEV-56286 test formulations compared to TEV-56286 reference product in healthy adult participants. The secondary objective is to evaluate the safety and tolerability of TEV-56286. The planned duration for each participant is approximately 70 days which includes a 45 day screening period.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
03/28/2025
Locations: Teva Investigational Site 12141, Miramar, Florida
Conditions: Healthy Participants
Register for Updates
A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
NCT06814132
Recruiting
The goal of the study is to learn what happens to levels of MK-5684 in people with severe renal impairment and end-stage renal disease versus a healthy person's body over time. Researchers will compare what happens to MK-5684 after hemodialysis in people with severe renal impairment and end-stage renal disease versus healthy people.
Gender:
MALE
Ages:
Between 18 years and 85 years
Trial Updated:
03/27/2025
Locations: Orlando Clinical Research Center ( Site 0002), Orlando, Florida +1 locations
Conditions: Kidney Failure, Chronic, End-Stage Kidney Disease, Renal Failure, Chronic, Renal Failure, End-Stage, Healthy Participants
Register for Updates
A Study to Investigate the Pharmacokinetics of AZD2389 When Administered Alone and in Combination With Itraconazole in Healthy Participants
NCT06846528
Recruiting
The purpose of this study is to assess the pharmacokinetics (PK) of AZD2389 when administered alone and in combination with itraconazole in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/27/2025
Locations: Research Site, Brooklyn, Maryland
Conditions: Healthy Participants
Register for Updates